Biotron’s Managing Director, Michelle Miller, said;
“The results from the extended, repeat Study 2 confirm the results from Study 1, showing a
clear clinical benefit from the treatment with BIT225.
Supported by these results, and in consultation with USA based advisors and consultants,
Biotron has submitted a proposal to the USA Food and Drug Administration (FDA) to conduct
a human clinical trial to assess the efficacy of BIT225 for the treatment of COVID-19 under
the Coronavirus Treatment Acceleration Program, a special emergency program for potential
coronavirus therapies.
Funding the clinical development of BIT225 for this indication will be sought from potential
partners and non-equity funding sources
In contrast, all mice in the control, drug-free group died by Day 8 post-infection with SARS-CoV-2 from severe COVID.
drug already passed safety phase one trials and also in HIV trials!
In summary, the in vivo results confirm previous findings that BIT225 inhibits SARS-
CoV-2 replication, reduces viral loads in the lungs and prevents development of severe
COVID-19 disease and death associated with SARS-CoV-2 infection in this animal model
of COVID-19
